Semaglutide and tirzepatide: what is the difference
A plain comparison of two GLP-1 medications by their mechanism class and how each is prescribed and monitored through telehealth. The right choice for any one person is a physician's decision after a medical intake.
If you have read about GLP-1 medications, you have probably seen both names come up. Semaglutide and tirzepatide are discussed together often, and for good reason. They belong to a related family of medications, and they are prescribed through similar telehealth and compounding pathways. They are also not identical. Here is a clear, plain look at how they differ, without any efficacy or dosing claims, because those are decisions a licensed physician makes with you.
The mechanism class, in plain terms
Both medications work on hormone pathways your body already uses to regulate appetite and blood sugar. The difference sits in how many of those pathways each one acts on.
Semaglutide is a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone involved in signaling fullness and managing glucose. Semaglutide mimics the action of that single receptor.
Tirzepatide acts on two receptors. It is a dual agonist that targets both GLP-1 and GIP, which stands for glucose-dependent insulinotropic polypeptide. GIP is a second incretin hormone that also plays a role in metabolism. So the simplest way to hold the distinction is this: semaglutide is single-pathway, tirzepatide is dual-pathway.
How each is prescribed
At Live Vital, both are physician-prescribed and reviewed by Dr. Patrick Taylor, MD. Neither is something you add to a cart. The process starts with a medical intake where you share your health history, current medications, and goals. A physician reviews that information and decides whether a GLP-1 medication is appropriate for you at all, and if so, which one.
When these medications are compounded, they are prescription products prepared by a licensed compounding pharmacy and dispensed only after physician approval. Compounded formulations are not FDA-approved, and where a particular use falls outside an approved label, it is off-label and physician-reviewed. A prescription is never guaranteed, and the answer after an intake is sometimes no.
You can read more on each option directly: semaglutide and tirzepatide.
How each is monitored
Monitoring looks similar for both, because both are GLP-1 class medications given by subcutaneous injection and both call for ongoing clinical oversight rather than a one-time handoff. A physician typically reviews how you are tolerating the medication, checks in on side effects, and adjusts the plan over time. Lab work may be part of that picture depending on your history.
Telehealth makes this practical across the country. Your check-ins happen remotely, your questions route back to the prescribing physician, and changes to your plan are clinical decisions, not self-service settings you toggle. That structure is the same whichever medication you are on.
So which one is right for you
That is genuinely not a question this article can answer, and any honest source will tell you the same. The choice depends on your medical history, your other medications, how your body responds, and a physician's judgment. Two people with similar goals can be directed toward different options, and outcomes vary by individual.
What you can do is get a qualified read on your own situation. A few billing notes while you are considering it: Live Vital does not accept insurance, and HSA or FSA funds are generally eligible to be used for these services.
One step you can take today
If you want to know whether either medication fits your health, start the medical screening, or book a free consult to ask questions first. A physician reviews your intake and determines everything that follows, including the medication, the plan, and whether a prescription is appropriate at all. This article is general information, not medical advice.